CHARLES FOULDS to Cyclin-Dependent Kinase 6
This is a "connection" page, showing publications CHARLES FOULDS has written about Cyclin-Dependent Kinase 6.
Connection Strength
0.454
-
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med. 2025 Aug 27; 17(813):eadq5492.
Score: 0.234
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
Score: 0.220